What is the product/service about?
Alex Therapeutics wants to perform a clinical trial to investigate the efficacy of Alex – Quit Smoking, a digital therapeutics smartphone application based on AI and Cognitive-Behavioral Therapy (CBT)
Where did the project idea come from?
The original idea behind Alex is to utilize technology to make evidence-based psychology available to everyone. We are an impact-driven company, and this project is ultimately about maximizing the impact of our product.
Why did you select that specific target country?
After launching the product in Sweden, we always envisioned entering a larger market with a large population of smokers. India is an obvious candidate. To enter this market which we know little about, we felt the need to perform a VAP.
Who are your partners in the target country?
We partner with the Public Health Foundation of India (PHFI). Together, we perform a clinical trial to investigate the efficacy of Alex – Quit Smoking, a digital therapeutics smartphone application based on AI and Cognitive-Behavioral Therapy (CBT), as a technique for tobacco cessation in India. The PHFI will lead the research project and recruit test users from workplaces using their networks and connections.
What is your long term vision for your company working in your chosen partner country?
To adapt our product to the market and establish ourselves as a leading DTx provider in India
What impact do you believe INNOWWIDE will have on your company?
It allows us to enter this very exciting market at a very early stage. Without INNOWWIDE it could have taken years before we had the resources and courage to do so with our own resources
Can you offer any advice or guidance to others looking to apply for INNOWWIDE grants?
The application is long and requires you to put in a fair amount of time if you want to stand a chance, but in return you can trust the reviewing committee to go through it in detail and provide you with valuable feedback along the way.